The development of antibodies and fusion proteins targeting the PD-1, PD-L1, and CTLA-4, collectively termed immune checkpoint inhibitors (ICI), has revolutionized cancer therapy, and their use as single-agent or combination therapies has significantly improved the outcomes for patients with a wide range of cancers (4, 5). Here, PDCD1 is linked to cancer.